U.S. markets open in 7 hours 18 minutes
  • S&P Futures

    -16.50 (-0.43%)
  • Dow Futures

    -129.00 (-0.42%)
  • Nasdaq Futures

    -47.75 (-0.40%)
  • Russell 2000 Futures

    -10.70 (-0.61%)
  • Crude Oil

    +0.65 (+0.65%)
  • Gold

    -0.80 (-0.05%)
  • Silver

    -0.18 (-0.92%)

    -0.0018 (-0.17%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.01 (+0.04%)

    -0.0035 (-0.30%)

    -0.7060 (-0.52%)

    -304.43 (-1.50%)
  • CMC Crypto 200

    -6.67 (-1.52%)
  • FTSE 100

    -207.18 (-2.86%)
  • Nikkei 225

    -276.34 (-1.05%)

Why Abiomed (ABMD) is a Top Growth Stock for the Long-Term

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Abiomed (ABMD)

Danvers, MA- headquartered Abiomed Inc. is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP. Impella 2.5 is primarily used by interventional cardiologists to support patients in the cardiac catheterization lab (cath lab) for partial circulatory support for up to six hours.

ABMD is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 4.1% year-over-year for the current fiscal year, with sales growth of 12.9%.

Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.02 to $4.62 per share. ABMD boasts an average earnings surprise of 7.9%.

On a historic basis, Abiomed has generated cash flow growth of 43.2%, and is expected to report cash flow expansion of 5% this year.

ABMD should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research